Report Categories
View AllRecent Articles
View All
ORGN Origin Materials stock rises 556 percent despite massively missing Q4 2025 consensus EPS estimates
CUB Lionheart CEO highlights strategic priorities growth initiatives amid quarterly earnings release with limited financial details
Vertex Pharmaceuticals Incorporated VRTX Casgevy Commercial Momentum and Pipeline Catalysts Signal Upside Ahead of Partner CRISPR Therapeutics Q1 2026 Earnings
BRCC BRC reports Q4 2025 EPS below consensus estimates shares post a 45 percent single day gain